The popular diabetes drug marketed as Avandia may increase bone thinning, a discovery that could help explain why diabetics can have an increased risk of fractures.
New research raises the possibility that long-term treatment with rosiglitazone, as Avandia is also called, could lead to osteoporosis. The diabetes drug is used to improved response to insulin.
Researchers found that in mice, the drug increased the activity of the cells that degrade bones, according to a report in this week’s online issue of Nature Medicine.
The finding “has led to a better understanding of the challenges associated with long-term treatment of patients with Type II diabetes,” said Ronald M. Evans of the Salk Institute for Biological Studies in La Jolla, Calif., lead author of the report.
“The long-term use of rosiglitazone should be cautious in patients with higher risk of fractures such as older women,” he added. Using it in combination with anti-osteoporosis drugs could be beneficial, he said.
(Source)
To curing many cancers in the world for more and more of these technological wonders of the extremely small world are making their debut to a clinic near you. These microscopic particles have been found to be very effective alternatives to current technology which attacks all cells that are encountered by the potent medication, healthy or cancerous. This indiscriminate attack results in the undesirable side-effects such as nausea and others that are the main detractors for such treatment options. The development of nano-bubbles that encapsulate these 
The mention of 
